TACH-101 is under clinical development by Tachyon Therapeutics and currently in Phase I for Esophageal Cancer. According to GlobalData, Phase I drugs for Esophageal Cancer have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how TACH-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TACH-101 (formerly QC8222) is under development for the treatment of solid tumors including advanced or metastatic cancer, metastatic colorectal cancer (CRC), esophageal cancer, gastric cancer, breast cancer, triple-negative breast cancer and Diffuse large B-cell lymphomas including germinal-center B-cell-like (GCB), activated B-cell-like (ABC) and primary mediastinal B-cell lymphoma (PMBL). It is administered through oral route. The drug candidate acts as pan-KDM4 epigenetic regulator.
Tachyon Therapeutics overview
Tachyon Therapeutics is a biotechnology company involved in therapeutics for the treatment of advanced cancers. Tachyon Therapeutics is headquartered in Houston, Texas, the US.
For a complete picture of TACH-101’s drug-specific PTSR and LoA scores, buy the report here.